Precision Pain Medicine

Two people with the same injury can need completely different treatments — and can react to the very same drug in opposite ways. Precision pain medicine aims to use your biology to guide care, replacing trial and error with something closer to a fit.

Your genes and your painkillers

The clearest example is already in your medical record’s reach. Codeine does nothing on its own — your body has to convert it into morphine, using an enzyme built by the gene CYP2D6. But people carry different versions of that gene. Poor metabolizers convert very little and get weak pain relief. Ultrarapid metabolizers convert too much, too fast — enough that the FDA carries a boxed warning after children died of respiratory depression following routine surgery.

This is not theoretical. National prescribing guidelines now advise avoiding codeine and tramadol entirely in poor and ultrarapid metabolizers, and pharmacogenomic testing for CYP2D6 exists to identify them in advance. It is precision pain medicine you can act on today — the same dose, a different gene, a completely different outcome.

Because codeine and tramadol are opioids, one note belongs here as much as anywhere: if you or someone you love is struggling with opioid or other substance use, the SAMHSA National Helpline is free, confidential, and open 24/7 at 1-800-662-HELP (4357).

Matching the drug to the mechanism

Precision is not only genetic. It also means matching the treatment to the kind of pain you have — the nociceptive, neuropathic, and nociplastic distinction in the three types of pain. A nerve-pain medicine will do little for a mechanical joint problem, and vice versa. Careful sensory testing can help sort out which pain system is misbehaving, pointing toward the treatments most likely to help before the trial-and-error even begins.

The search for an objective signal

Pain has no blood test — and a great deal of research is trying to change that. Quantitative sensory testing, brain and nerve imaging, and candidate blood markers are all being studied as biomarkers that could confirm a pain mechanism, predict who will respond to a given treatment, or flag who is at risk of pain becoming chronic. None is ready for routine clinic use yet, but even a rough objective signal would change how pain is diagnosed.

Where AI fits — carefully

Machine learning is being applied to some of these problems: reading imaging, spotting patterns across large datasets, and estimating the risk that acute pain will turn chronic. It is early, and it carries real risks of bias if trained on incomplete data — pain has a long history of being under-recognized in some groups. Treated as a tool to support clinicians rather than replace judgment, it may help target care; oversold, it could entrench old inequities.

From the average patient to you

The common thread is a shift away from treating an average patient and toward treating you — your genes, your pain mechanism, your risk. Many of the new drugs in the pain treatment pipeline are being built for specific patient groups from the start — precision by design.